Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 425

Sort by

Sort Order Select

Journal Articles

Radiomics-based identification of high-risk disease in newly diagnosed multiple myeloma

Guneet Janda, Emmanuel Contreras Guzman, Michael Howe, Jacob Shreve, Surendra Dasari, Nadine Abdallah, Wilson Gonsalves, Francis Buadi, Joselle Cook, Taxiarchis Kourelis, Suzanne Hayman, Morie Gertz, Rafael Fonseca, Angela Dispenzieri, S. Vincent Rajkumar, Matthew Thorpe, Shaji Kumar, Moritz Binder

Blood (2025) 146 (Supplement 1): 924.

https://doi.org/10.1182/blood-2025-924

Published: 2025

Journal Articles

Identifying high-risk profiles and adverse prognoses in relapsed/refractory multiple myeloma treated with bispecific antibodies: A real-world analysis of 943 treatment initiations

Blood (2025) 146 (Supplement 1): 4069.

https://doi.org/10.1182/blood-2025-4069

Published: 2025

Journal Articles

Mapping the immune checkpoint receptor-ligand landscape in newly diagnosed multiple myeloma may help prioritize patients for immune checkpoint inhibitor therapy

Steven Foltz, Reyka Jayasinghe, MMRF Immune Atlas Network, David Avigan, Samir Parekh, Ravi Vij, Shaji Kumar, Taxiarchis Kourelis, Sagar Lonial, Hearn Cho, Ioannis Vlachos, Sacha Gnjatic, Li Ding, Manoj Bhasin, Chaitanya Acharya, Alexander Gout, George Mulligan

Blood (2025) 146 (Supplement 1): 4024.

https://doi.org/10.1182/blood-2025-4024

Published: 2025

Journal Articles

Altered bone marrow (BM) plasma amino acid (AA) composition reflects microenvironmental remodeling in patients with multiple myeloma (MM) compared to monoclonal gammopathy of unknown significance (MGUS)

Michael Egan, Yogesh Chawla, Puja Dey, Dragan Jevremovic, Taro Hitosugi, Shaji Kumar, Wilson Gonsalves

Blood (2025) 146 (Supplement 1): 2149.

https://doi.org/10.1182/blood-2025-2149

Published: 2025

Journal Articles

Machine learning–driven prognostication of overall survival at 6 months after CAR-T cell therapy

Blood (2025) 146 (Supplement 1): 2563.

https://doi.org/10.1182/blood-2025-2563

Published: 2025

Journal Articles

Clinical course, predictors of development, and therapeutic response in multiple myeloma with central nervous system involvement

Blood (2025) 146 (Supplement 1): 2225.

https://doi.org/10.1182/blood-2025-2225

Published: 2025

Journal Articles

Correlative biomarker analyses of etentamig in patients with Relapsed/Refractory multiple myeloma (RRMM) at optimal dose support its potential to maximize T-cell activity with rapid and transient proinflammatory cytokine responses

Blood (2025) 146 (Supplement 1): 2204.

https://doi.org/10.1182/blood-2025-2204

Published: 2025

Journal Articles

Cytogenetics-based clinical trajectories of patients with MRD negativity post autologous stem cell transplant for multiple myeloma

Blood (2025) 146 (Supplement 1): 362.

https://doi.org/10.1182/blood-2025-362

Published: 2025

Journal Articles

Large language model for abstraction of CAR-T therapy toxicities data

Blood (2025) 146 (Supplement 1): 6139.

https://doi.org/10.1182/blood-2025-6139

Published: 2025

Journal Articles

Real-world (RW) outcomes of newly diagnosed multiple myeloma (NDMM) patients (pts) treated with front-line daratumumab (dara), bortezomib (bor), lenalidomide (len) and dexamethasone (dex) (DVRd)

Blood (2025) 146 (Supplement 1): 4585.

https://doi.org/10.1182/blood-2025-4585

Published: 2025

Journal Articles

Disease characteristics, treatment patterns, and outcomes of AL amyloidosis patients with high-risk FISH cytogenetics

Blood (2025) 146 (Supplement 1): 5741.

https://doi.org/10.1182/blood-2025-5741

Published: 2025

Journal Articles

Efficacy and safety of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma and extramedullary disease: Updated Phase 2 results from the redirectt-1 study with extended follow-up

Blood (2025) 146 (Supplement 1): 698.

https://doi.org/10.1182/blood-2025-698

Published: 2025

Journal Articles

Association between cilta-cel dose and efficacy and toxicity outcomes for patients with Relapsed/Refractory multiple myeloma (RRMM): A real-world analysis from the US multiple myeloma immunotherapy consortium

Ran Reshef, Alexandria Jensen, Christian Gordillo, Brett Reid, Danai Dima, Lauren Peres, Mahmoud Gaballa, Rahul Banerjee, Oren Pasvolsky, Aimaz Afrough, Christen Dillard, Christopher Ferreri, Shebli Atrash, Cindy Varga, Andrew Portuguese, Masooma Rana, Hitomi Hosoya, Lekha Mikkilineni, Vanna Hovanky, Saurabh Zanwar, Nilesh Kalariya, Damian Mikulski, Charlotte Wagner, Christopher Cahoon, Omar Puglianini, Gabriel De Avila, Eli Zolotov, Evguenia Bhurtel, Ariel Grajales-Cruz, Utkarsh Goel, Aishwarya Sannareddy, Jeries Kort, Raffaella Cassano, Shonali Midha, James Davis, Rebecca Gonzalez, Megan Herr, Zhuoer Xie, Hamza Hassan, Sneha Purvey, Marcus Geer, Kimberly Green, Fabiana Perna, Hien Liu, Taiga Nishihori, Jack Khouri, Shahzad Raza, Faiz Anwer, Susan Bal, Omar Nadeem, Ciara Louise Freeman, Leyla Shune, Kenneth Shain, Melissa Alsina, Rachid Baz, Douglas Sborov, Saurabh Dahiya, Frederick Locke, David Miklos, Peter Voorhees, Larry Anderson, Luciano Costa, Noa Biran, Shaji Kumar, Yi Lin, Krina Patel, Doris Hansen, Surbhi Sidana

Blood (2025) 146 (Supplement 1): 134.

https://doi.org/10.1182/blood-2025-134

Published: 2025

Journal Articles

Patient perspectives and preferences for step-up dosing and treatment with teclistamab and talquetamab: Insights from a patient survey

Jay Hydren, Rachel Jensen, Jorge Arturo Hurtado Martinez, Jennifer Ahlstrom, Mason Barnes, Caitlin Costello, Gurbakhash Kaur, Meera Mohan, Francesca Cottini, Douglas Sborov, Shaji Kumar, Noopur Raje, Philippe Moreau, Maithili Deshpande, Niodita Gupta-Werner, Tonya Le Blanc, Jessica Fowler, Rahul Banerjee

Blood (2025) 146 (Supplement 1): 6354.

https://doi.org/10.1182/blood-2025-6354

Published: 2025

Journal Articles

Combinations of high risk cytogenetic events in multiple myeloma drive distinct immune remodeling patterns and worse outcomes

Blood (2025) 146 (Supplement 1): 2179.

https://doi.org/10.1182/blood-2025-2179

Published: 2025

Journal Articles

Tumor intrinsic mechanisms leading to cevostamab resistance in multiple myeloma

Blood (2025) 146 (Supplement 1): 2178.

https://doi.org/10.1182/blood-2025-2178

Published: 2025

Journal Articles

Genomics define neoplastic transformation in multiple myeloma precursor conditions

Blood (2025) 146 (Supplement 1): 686.

https://doi.org/10.1182/blood-2025-686

Published: 2025

Journal Articles

AI multimodal large language model on CAR-T pre-leukapheresis evaluation to predict monitoring needs post infusion for early dismissal planning

Blood (2025) 146 (Supplement 1): 6131.

https://doi.org/10.1182/blood-2025-6131

Published: 2025

Journal Articles

Anti-platelet factor 4 antibodies in MGUS-related thrombosis

Adam Kanack, Noah Splinter, Damon Houghton, Emily Mauch, Rachel Leger, Surbhi Shah, Angela Dispenzieri, Shaji Kumar, Rajiv Pruthi, Dong Chen, Anand Padmanabhan

Blood (2025) 146 (Supplement 1): 1321.

https://doi.org/10.1182/blood-2025-1321

Published: 2025

Journal Articles

Identifying candidates for outpatient administration of ciltacabtagene autoleucel (Cilta-cel) in relapsed-refractory multiple myeloma (RRMM)

Danai Dima, Lauren Peres, Leyla Shune, Christelle Leitzinger, Brett Reid, Andrew Portuguese, Raffaella Cassano Cassano, Rahul Banerjee, Nilesh Kalariya, Oren Pasvolsky, Mahmoud Gaballa, Zachary Hunzeker, Christen Dillard, Hitomi Hosoya, Lekha Mikkilineni, Rebecca Gonzalez, Ariel Grajales-Cruz, Omar Alexis Castaneda Puglianini, Taiga Nishihori, Charlotte Wagner, Christopher Cahoon, Douglas Sborov, Evguenia Bhurtel, Jeries Kort, Marcus Geer, Sneha Purvey, Christopher Ferreri, Cindy Varga, Shebli Atrash, Peter Voorhees, Utkarsh Goel, Jack Khouri, Shahzad Raza, Faiz Anwer, Aimaz Afrough, Aishwarya Sannareddy, Larry Anderson, Hamza Hassan, Megan Herr, Ran Reshef, Christian Gordillo, Eli Zolotov, Noa Biran, James Davis, Kimberly Green, Saurabh Zanwar, Yi Lin, Luciano Costa, Susan Bal, Shonali Midha, Omar Nadeem, Melissa Alsina, Rachid Baz, Kenneth Shain, Frederick Locke, Shaji Kumar, Krina Patel, Surbhi Sidana, Doris Hansen

Blood (2025) 146 (Supplement 1): 4000.

https://doi.org/10.1182/blood-2025-4000

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Radiomics-based identification of high-risk disease in newly diagnosed multiple myeloma

Identifying high-risk profiles and adverse prognoses in relapsed/refractory multiple myeloma treated with bispecific antibodies: A real-world analysis of 943 treatment initiations

Mapping the immune checkpoint receptor-ligand landscape in newly diagnosed multiple myeloma may help prioritize patients for immune checkpoint inhibitor therapy

Altered bone marrow (BM) plasma amino acid (AA) composition reflects microenvironmental remodeling in patients with multiple myeloma (MM) compared to monoclonal gammopathy of unknown significance (MGUS)

Machine learning–driven prognostication of overall survival at 6 months after CAR-T cell therapy

Clinical course, predictors of development, and therapeutic response in multiple myeloma with central nervous system involvement

Correlative biomarker analyses of etentamig in patients with Relapsed/Refractory multiple myeloma (RRMM) at optimal dose support its potential to maximize T-cell activity with rapid and transient proinflammatory cytokine responses

Cytogenetics-based clinical trajectories of patients with MRD negativity post autologous stem cell transplant for multiple myeloma

Large language model for abstraction of CAR-T therapy toxicities data

Real-world (RW) outcomes of newly diagnosed multiple myeloma (NDMM) patients (pts) treated with front-line daratumumab (dara), bortezomib (bor), lenalidomide (len) and dexamethasone (dex) (DVRd)

Disease characteristics, treatment patterns, and outcomes of AL amyloidosis patients with high-risk FISH cytogenetics

Efficacy and safety of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma and extramedullary disease: Updated Phase 2 results from the redirectt-1 study with extended follow-up

Association between cilta-cel dose and efficacy and toxicity outcomes for patients with Relapsed/Refractory multiple myeloma (RRMM): A real-world analysis from the US multiple myeloma immunotherapy consortium

Patient perspectives and preferences for step-up dosing and treatment with teclistamab and talquetamab: Insights from a patient survey

Combinations of high risk cytogenetic events in multiple myeloma drive distinct immune remodeling patterns and worse outcomes

Tumor intrinsic mechanisms leading to cevostamab resistance in multiple myeloma

Genomics define neoplastic transformation in multiple myeloma precursor conditions

AI multimodal large language model on CAR-T pre-leukapheresis evaluation to predict monitoring needs post infusion for early dismissal planning

Anti-platelet factor 4 antibodies in MGUS-related thrombosis

Identifying candidates for outpatient administration of ciltacabtagene autoleucel (Cilta-cel) in relapsed-refractory multiple myeloma (RRMM)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only